- Home
- Signaling Pathways
- Metabolism
- PPAR
- Fenofibrate
Fenofibrate
- 1. Shicheng Fan, Yue Gao, et al. "Fenofibrate-promoted hepatomegaly and liver regeneration are PPARα-dependent and partially related to the YAP pathway." Acta Pharmaceutica Sinica B Volume 14, Issue 7, July 2024, Pages 2992-3008 PMID: 39027236
- 2. Yi-Han Zhang, Jun-Yi Xian, et al. "Hydroxycitric acid inhibits kidney stone through crystallization regulation and reduction of hyperoxalate-induced lipotoxicity." Journal of Functional Foods. Volume 105, June 2023
- 3. Wang L, Xie H, et al. "rSj16 Protects against DSS-Induced Colitis by Inhibiting the PPAR-α Signaling Pathway." Theranostics. 2017 Aug 15;7(14):3446-3460. PMID:28912887
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 360.83 |
| Cas No. | 49562-28-9 |
| Formula | C20H21ClO4 |
| Solubility | insoluble in H2O; ≥12.75 mg/mL in DMSO; ≥18.57 mg/mL in EtOH |
| Chemical Name | propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate |
| SDF | Download SDF |
| Canonical SMILES | CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
MCF-7 and Panc-1 cells |
|
Preparation method |
The solubility of this compound in DMSO is > 12.8 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
24, 48 and 72 hrs |
|
Applications |
At 24th, 48th and 72th hrs, the IC50 values of Fenofibrate were 96.6, 46.5 and 9.2 μg/mL on Panc-1 cells, and 93.5, 55.9 and 8 μg/mL on MCF-7 cells, respectively. Compared with the untreated solvent control, MCF-7 and Panc-1 cells treated with 1/2 IC50, IC50 and 2 IC50 of Fenofibrate for 24 hrs exhibited a significant increase in the relative activity of caspase 3/7. |
| Animal experiment [1]: | |
|
Animal models |
Mice bearing Ehrlich ascites carcinoma (EAC) |
|
Dosage form |
200 mg/kg/day; p.o.; for 18 days |
|
Applications |
In an EAC mouse model, Fenofibrate significantly reduced tumor weight and volume, without affecting the relative heart weight. However, Fenofibrate treatment significantly decreased the body weight and increased the relative liver weight. In addition, a marked decrease in the carcinoembryonic antigen (CEA) level was also observed in the Fenofibrate treatment group. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Sabaa M, ELFayoumi HM, Elshazly S, Youns M, Barakat W. Anticancer activity of salicin and fenofibrate. Naunyn Schmiedebergs Arch Pharmacol. 2017 Jul 21. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
